BLU-554

Overview

BLU-554 is a selective covalent inhibitor of FGFR4 (FGFR4), designed to exploit FGF19/FGFR4 signaling in hepatocellular carcinoma (HCC). FGF19 gene amplification (~5–10% of HCCs) and protein overexpression detected by IHC serve as enrollment biomarkers.

Evidence in the corpus

• In HCC, BLU-554 produced a 16% response rate in FGFR4-driven (≥1% FGF19 IHC) patients vs 0% in FGFR4-negative patients; FGF19 expression by IHC required for enrichment PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.